<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01476878</url>
  </required_header>
  <id_info>
    <org_study_id>FRAMELESS SRS</org_study_id>
    <nct_id>NCT01476878</nct_id>
  </id_info>
  <brief_title>Frameless Stereotactic Radiosurgery for Brain Metastases</brief_title>
  <official_title>Frameless Stereotactic Radiosurgery for Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tom Baker Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to study high dose, single treatment radiation, using a plastic mask
      instead of a head frame that pins into a patient's skull. The investigators need to (1)
      quantify set-up accuracy and patient motion during radiation treatment and (2) ensure that
      without the head frame the tumour control rate and risk of complications are similar to our
      previous experience using the head frame.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of patient movement occurring during treatment.</measure>
    <time_frame>overall</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tumour control</measure>
    <time_frame>overall</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk of complication (radionecrosis)</measure>
    <time_frame>overall</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Open Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Frameless Stereotactic Radiosurgery with radiation mask</intervention_name>
    <description>Linac-based radiosurgery using a thermoplastic mask (single treatment)</description>
    <arm_group_label>Open Arm</arm_group_label>
    <other_name>Frameless Stereotactic Radiosurgery using radiation mask</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with brain metastases from a biopsy-proven primary extra-cranial tumor site,
             excluding lymphoma, germ cell, and small cell lung carcinoma histologies.

          -  One to four metastases, and all lesions &lt; 3.5 cm in maximal diameter. Extracranial
             metastases is of minimal volume or stable with treatment. - Karnofsky performance
             status â‰¥ 70

        Exclusion Criteria:

          -  None of the lesions is abutting or within critical neurological structures: *brainstem

               -  optic chiasm

               -  eye, and optic nerve.

          -  The clearance between metastatic lesions and all critical structures must be at least
             2 mm.

          -  Patients must not have leptomeningeal disease.

          -  Contraindications to imaging or radiation (e.g. pregnancy, elevated serum creatinine,
             allergy to contrast agents, severe claustrophobia, metal particles in the eye).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon-Paul Voroney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tom Baker Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jon-Paul Voroney, Phd. M.D.</last_name>
    <phone>403-521-3164</phone>
    <email>Jon-Paul.Voroney@albertahealthservices.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jon-Paul Voroney, PHD. M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harold Lau, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>November 18, 2011</last_update_submitted>
  <last_update_submitted_qc>November 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jon-Paul Voroney</name_title>
    <organization>Tom Baker Cancer Centre</organization>
  </responsible_party>
  <keyword>Radiosurgery</keyword>
  <keyword>Frameless radiosurgery</keyword>
  <keyword>Accuracy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

